Teva Sues FDA For Excluding Copaxone From BLA Transition

Israeli Firm Wants To Use Biosimilar Litigation Process

 
• By Brenda Sandburg
  
Generate a summary of this article
Listen to this article
Beta

Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.

Medical needles of Copaxone
Teva Wants Copaxone To Be Deemed A Biologic • Source: Shutterstock

The day after the US Food and Drug Administration switched nearly 100 new drug applications from being regulated as drugs to biologics, Teva filed suit against the agency for excluding Copaxone (glatiramer acetate injection) from the transition list. While generics of the multiple sclerosis treatment are already on the market, Teva would like to use the biosimilar litigation process to prevent further generics from launching.

The complaint, filed on 24 March in the US District Court for the District of Columbia, says that had...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By Nabil

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By Akriti Seth

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By David Wallace

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin